{"entity":{"id":"nct07570914","kind":"trial","name":"Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases","aka":[],"tldr":"A phase 2 trial of irinotecan (and liposomal irinotecan), fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","summary":"Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases is a phase 2, interventional study registered as NCT07570914 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 28 participants, started 2026-05-30 and due to reach its primary completion in 2027-05-30. Interventions recorded: Liposomal Irinotecan; Oxaliplatin; Capecitabine; hepatic arterial infusion chemotherapy (HAIC). Conditions listed: Colorectal Cancer Liver Metastases (CRLM); Colorectal Cancer; Liver Metastasis. Primary outcome: 3-Year Disease-Free Survival Rate. Colorectal eligibility wording from the registry: \"Completion of radical resection of the colorectal primary tumor and liver metastases within 12 weeks before enrollment, with postoperative imaging showing no residual lesion, recurrence, or extrahepatic metastasis, indicating no evidence of disease\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07570914","url":"https://clinicaltrials.gov/study/NCT07570914"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":[],"drugs":["irinotecan","folfox","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07570914","phase":"2","setting":"An Exploratory Clinical Study of Hepatic Arterial Infusion of Liposomal Irinotecan Combined With Oxaliplatin and Capecitabine as Postoperative Adjuvant Therapy for Colorectal Cancer Liver Metastases","sponsor":"Tianjin Medical University Cancer Institute and Hospital","enrolled":28,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07570914/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"irinotecan","kind":"drug","name":"Irinotecan (and liposomal irinotecan)","route":"/drugs/irinotecan/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}